FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma

doi:10.3748/wjg.v21.i7.2096

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 7

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7026)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

670

WORD

227

HTML

3950

Figures (1-1)

146

Tables (1-2)

146

Sum=5139

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

950

Download

937

Sum=1887

Feb 21, 2015 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (51)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Feb 21, 2015; 21(7): 2096-2101
Published online Feb 21, 2015. doi: 10.3748/wjg.v21.i7.2096

Table 2 Observed toxicity according National Cancer Institute Common Terminology Criteria for adverse events grading (n = 12)

	NCI-CTC grade
	All grades	Severe¹
Hematological
Anemia	5	0
Neutropenia	7	3
Thrombocytopenia	6	2
Non hematological
Nausea/vomiting	6	0
Mucositis	1	0
Diarrhea	5	2
Infection	0	0
Nose bleeding	2	0
High blood pressure	2	0

¹Grade 3-4 according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTC) version 2.0 scale.

Citation: Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101
URL: https://www.wjgnet.com/1007-9327/full/v21/i7/2096.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i7.2096